Terms: = Pancreatic cancer AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK AND Clinical Outcome
12 results:
1. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer.
Xiong Q; Zhou Y; Zhang S; Zhang Y; Xu Y; Yang Y; Zhou C; Zeng Z; Han J; Zhu Q
Cancer Med; 2023 May; 12(9):10961-10978. PubMed ID: 37062069
[TBL] [Abstract] [Full Text] [Related]
2. miRNA‑7515 suppresses pancreatic cancer cell proliferation, migration and invasion via downregulating IGF‑1 expression.
Lei S; Zeng Z; He Z; Cao W
Oncol Rep; 2021 Sep; 46(3):. PubMed ID: 34296285
[TBL] [Abstract] [Full Text] [Related]
3. Lumican, pro-tumorigenic or anti-tumorigenic: A conundrum.
Appunni S; Rubens M; Ramamoorthy V; Anand V; Khandelwal M; Saxena A; McGranaghan P; Odia Y; Kotecha R; Sharma A
Clin Chim Acta; 2021 Mar; 514():1-7. PubMed ID: 33333043
[TBL] [Abstract] [Full Text] [Related]
4. Hypoxia-driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial-mesenchymal transition and cancer stem cell-like properties by modulating forkhead box protein M1.
Cao J; Li J; Sun L; Qin T; Xiao Y; Chen K; Qian W; Duan W; Lei J; Ma J; Ma Q; Han L
Mol Oncol; 2019 Feb; 13(2):228-245. PubMed ID: 30367545
[TBL] [Abstract] [Full Text] [Related]
5. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
[TBL] [Abstract] [Full Text] [Related]
6. Expression of the scaffold connector enhancer of kinase suppressor of Ras 1 (CNKSR1) is correlated with clinical outcome in pancreatic cancer.
Quadri HS; Aiken TJ; Allgaeuer M; Moravec R; Altekruse S; Hussain SP; Miettinen MM; Hewitt SM; Rudloff U
BMC Cancer; 2017 Jul; 17(1):495. PubMed ID: 28732488
[TBL] [Abstract] [Full Text] [Related]
7. Asporin promotes pancreatic cancer cell invasion and migration by regulating the epithelial-to-mesenchymal transition (EMT) through both autocrine and paracrine mechanisms.
Wang L; Wu H; Wang L; Zhang H; Lu J; Liang Z; Liu T
Cancer Lett; 2017 Jul; 398():24-36. PubMed ID: 28400334
[TBL] [Abstract] [Full Text] [Related]
8. The flavonoid p-hydroxycinnamic acid exhibits anticancer effects in human pancreatic cancer MIA PaCa-2 cells in vitro: Comparison with gemcitabine.
Yamaguchi M; Murata T; El-Rayes BF; Shoji M
Oncol Rep; 2015 Dec; 34(6):3304-10. PubMed ID: 26397991
[TBL] [Abstract] [Full Text] [Related]
9. Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer.
Qin R; Smyrk TC; Reed NR; Schmidt RL; Schnelldorfer T; Chari ST; Petersen GM; Tang AH
Br J Cancer; 2015 Feb; 112(3):514-22. PubMed ID: 25584484
[TBL] [Abstract] [Full Text] [Related]
10. Novel synthetic oleanane triterpenoid AMR-MeOAc inhibits K-Ras through erk, Akt and survivin in pancreatic cancer cells.
Rabi T; Venkatanarashiman M
Phytomedicine; 2014 Mar; 21(4):491-6. PubMed ID: 24215674
[TBL] [Abstract] [Full Text] [Related]
11. Phosphorylation status of heat shock protein 27 plays a key role in gemcitabine-induced apoptosis of pancreatic cancer cells.
Nakashima M; Adachi S; Yasuda I; Yamauchi T; Kawaguchi J; Itani M; Yoshioka T; Matsushima-Nishiwaki R; Hirose Y; Kozawa O; Moriwaki H
Cancer Lett; 2011 Dec; 313(2):218-25. PubMed ID: 21999932
[TBL] [Abstract] [Full Text] [Related]
12. pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response.
Tzeng CW; Frolov A; Frolova N; Jhala NC; Howard JH; Vickers SM; Buchsbaum DJ; Heslin MJ; Arnoletti JP
Ann Surg Oncol; 2007 Jul; 14(7):2150-8. PubMed ID: 17453292
[TBL] [Abstract] [Full Text] [Related]